Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Mr. Jacob Thaysen est le Chief Executive Officer de Illumina Inc, il a rejoint l'entreprise depuis 2023.
Quelle est la performance du prix de l'action ILMN ?
Le prix actuel de ILMN est de $176.29, il a 下降 de 0.14% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Illumina Inc ?
Illumina Inc appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de Illumina Inc ?
La capitalisation boursière actuelle de Illumina Inc est de $26.6B
Est-ce que Illumina Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 22 analystes ont établi des notations d'analystes pour Illumina Inc, y compris 8 achat fort, 6 achat, 13 maintien, 2 vente et 8 vente forte